JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB315825

Anti-AAV9 抗体 [HL2374-IgG1]

Anti-AAV9 antibody [HL2374-IgG1]

Be the first to review this product! Submit a review

|

(0 Publication)

Mouse Recombinant Monoclonal AAV9 antibody. Suitable for I-ELISA, Dot and reacts with Recombinant fragment - Adeno-associated virus 9 samples.

別名を表示する

Adeno-associated virus - 9

2 Images
Indirect ELISA - Anti-AAV9 antibody [HL2374-IgG1] (AB315825)
  • I-ELISA

Lab

Indirect ELISA - Anti-AAV9 antibody [HL2374-IgG1] (AB315825)

This data was developed using ab315826, the same antibody clone in a different buffer formulation.

Indirect ELISA showing ab315826 binding to AAV9 empty capsid. Binding of ab315826 was assessed in a serial dilution and EC-50 is 8.62 ng/ml. The secondary antibody used was Goat Anti-Mouse IgG H&L (HRP) preadsorbed at 1/2000 dilution.

Antigen : AAV1 empty capsid,AAV2 empty capsid,AAV3B empty capsid,AAV5 empty capsid,AAV6 empty capsid,AAV8 empty capsid,AAV9 empty capsid.

Antigen concentration : 7.5E+10 vp/mL

Dot Blot - Anti-AAV9 antibody [HL2374-IgG1] (AB315825)
  • Dot

Supplier Data

Dot Blot - Anti-AAV9 antibody [HL2374-IgG1] (AB315825)

This data was developed using ab315826, the same antibody clone in a different buffer formulation.

Dot blot analysis of AAV9 using ab315826 at 1 : 2000 (0.5 ug/ml) followed by a Peroxidase-Conjugated Goat anti-Mouse IgG (H+L) at 1 : 5000 dilution.

Dot blot was performed using 1 ng of each capsid loaded per well.

Anti-AAV9 antibody [HL2368] (ab315818) (1 : 2000), Anti-AAV9 antibody [HL2370] (ab315820) (1 : 2000), Anti-AAV9 antibody [HL2374] (ab315823) (1 : 2000), and Anti-AAV9 antibody [HL2374-IgG1] - BSA and Azide free (ab315826) (1 : 2000) specifically recognize AAV9 capsid.

Anti-AAV8 + AAV3B antibody [HL2383] (ab315827) (1 : 2000), and Anti-AAV8 + AAV3B antibody [HL2383-IgG1] (ab315829) (1 : 2000) specifically recognize AAV8/3B capsid.

Anti-AAV8 + AAV9 antibody [HL2372] (ab315821) (1 : 2000) specifically recognizes AAV8/9 capsid.

Anti-AAV5 antibody [HL2476] (ab315831) (1 : 2000) specifically recognizes AAV5 capsid.

false

Exposure time: 8min

関連する標識済み抗体及び組成の異なる製品 (1)

  • Carrier free

    Anti-AAV9 antibody [HL2374-IgG1] - BSA and Azide free

Key facts

宿主種

Mouse

クローン性

Monoclonal

クローン番号

HL2374-IgG1

アイソタイプ

IgG1

キャリアフリー

No

交差種

Adeno-associated virus 9

アプリケーション

I-ELISA, Dot

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Adeno-associated virus 9": { "IELISA-species-checked": "predicted", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "Dot-species-checked": "predicted", "Dot-species-dilution-info": "", "Dot-species-notes": "" }, "Recombinant fragment - Adeno-associated virus 9": { "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "<p></p>", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "<p></p>" } } }
style
left-column

製品の詳細

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Ion exchange chromatography
バッファー組成
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Adeno-associated virus serotype 9 (AAV9) is a viral vector used in gene therapy known for its ability to transduce cells by delivering genetic material. Popular as a genetic tool AAV9 is utilized because of its efficient transfection capabilities in a variety of tissues. It consists of a protein capsid which forms an icosahedral structure important for its ability to encapsulate and deliver therapeutic DNA. The AAV9 capsid has an approximate molecular mass of 60 kilodaltons per subunit assembling into a larger capsid particle. AAV9 exhibits a broad expression profile being able to transduce diverse tissues including muscle liver central nervous system and cardiac tissues.
Biological function summary

AAV9 targets enable the efficient delivery of genes by trafficking across the cellular barriers leading to gene expression within target cells. Part of the larger family of adeno-associated viruses AAV9's specificity for different tissues allows researchers to target certain organs for therapeutic purposes. The AAV9 capsid engages with cell surface receptors and undergoes internalization by endocytosis. Interestingly different serotypes within this family vary slightly in tissue tropism and selection of the appropriate serotype affects therapeutic outcomes.

Pathways

AAV9 interacts with cellular regulatory mechanisms involved in transporting genetic material to the nucleus where it integrates into the genome or exists episomally. It is notably applied in pathways related to muscle and CNS diseases where AAV9 enhances the delivery of therapeutic genes. It operates in conjunction with certain cellular proteins that facilitate endosomal escape and nuclear entry making it effective for addressing genetic defects linked with these pathways.

AAV9 has been linked to therapeutic strategies for conditions such as spinal muscular atrophy (SMA) and certain types of muscular dystrophy. Utilization of AAV9 allows for the delivery of corrective genes potentially reversing or halting disease progression. In SMA for example AAV9 is used to deliver survival motor neuron (SMN) gene which is deficient in patients. Similarly in muscular dystrophy AAV9 aids in the administration of dystrophin or microdystrophin genes which play an important role in muscle integrity and function.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

See full target information AAV9
style
left-column
style
left-column
style
right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com